GeneCapture technology directed at rapid treatment of wound infections
 

December 16, 2020 (Huntsville, Ala.) – GeneCapture and subcontractor Canvas Inc. were recently awarded a $250,000 Phase I Small Business Innovative Research (SBIR) contract from the Defense Health Agency (DHA) for feasibility testing of GeneCapture’s rapid portable Infection Diagnostic (ID) and Antibiotic Susceptibility Test (AST). DHA is seeking ways to quickly diagnose and accurately treat wound infections in civilians and in injured Warfighters. GeneCapture’s ID and AST platform will enable medical providers of all skill levels to treat infections with the appropriate antibiotics at the Point of Care.

The rapid treatment of an infection with the right drug is critical to the fight against global antimicrobial resistance (AMR.)  The pathogens of interest to the DHA are the ESKAPE pathogens – Enterococcus spp., Staphylococcusaureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp., and Escherichia coli. Multidrug resistant ESKAPE pathogens contribute to AMR world-wide and pose a critical threat to the Warfighter.      

“Wound infections can be fatal. DHA is seeking to address this problem with novel solutions that combine identifying the pathogen and determining which antibiotic works best, both right at the Point of Care.  Antimicrobial resistance is a serious, global problem, and GeneCapture is pleased to have been selected to demonstrate our lab-free approach for this Phase I study,” states GeneCapture Chief Scientist Paula Millirons.

Subcontractor Canvas Inc. brings software development, AI/machine learning, image processing and microbiology expertise to support GeneCapture in developing pathogen fingerprints from the CAPTURE assay data. Canvas and GeneCapture have collaborated on previous biotech projects to bring infection detection solutions to the Point of Care.

GeneCapture has developed the CAPTURE assay (Confirm Active Pathogens Through Unamplified RNA Expression), which uses a novel non-PCR protocol to quickly identify a pathogen’s RNA from a custom library of probes on a microarray. Now GeneCapture’s platform will also include a breakthrough AST assay providing rapid on-site testing of various antibiotics once the single or mixed pathogens have been identified. Both assays are designed to operate in remote environments without refrigeration or a lab infrastructure.

Photo caption: GeneCapture and Canvas microbiologists prepare experiments to demonstrate rapid identification and antibiotic susceptibility for pathogens of interest to Defense Health Agency.

###

About GeneCapture: 
Gene Capture is developing a rapid infection detection device for use in point of care medicine.  Using a “Genetic Signature Match” Gene Capture has been able to detect multiple infectious pathogens in human samples in about an hour.  The GeneCapture technique detects the RNA of the pathogen, which indicates that the organism is alive; a major benefit of the platform. Recently, the GeneCapture team developed a rapid antibiotic susceptibility test for use in point of care and remote applications.  GeneCapture’s labs are on the campus of HudsonAlpha Institute for Biotechnology. The early technology was developed at The University of Alabama in Huntsville.  For more information see www.genecapture.com.

About Canvas:
Canvas, Inc., a Huntsville-based Woman-Owned Small Business, provides Engineering and Technical Services to a diverse group of customers in the areas Systems Engineering, Software Engineering, Biomedical Engineering, Test and Evaluation, Technology and Product Development, and Warfighter Operations Management. Canvas was named Government Contracting Technology Business of the Year (2018) and Woman-Owned Small Business of the Year (2018) by the Huntsville/Madison Chamber of Commerce. For more information see www.canvas-inc.com.

About HudsonAlpha:
About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha’s vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 40 diverse biotech companies on campus. To learn more about HudsonAlpha, visit hudsonalpha.org.

December 2, 2020 (Huntsville, Ala.) – The HudsonAlpha Foundation and Mrs. Linda Smith announce the creation of the Smith Family Chair in Genomics at the HudsonAlpha Institute for Biotechnology. The Smith Family Chair in Genomics will be held by Greg Barsh, MD, PhD, faculty investigator at HudsonAlpha.

“I am so glad to continue to support HudsonAlpha,” said Smith. “I am delighted that this chair will support Dr. Barsh’s work and new discoveries in science.”

Linda and her husband, the late Mark C. Smith, moved to Huntsville, Ala. after meeting at the Georgia Institute of Technology. Mr. Smith started two successful companies in the Huntsville community, as the founder of Universal Data Systems and co-founder of ADTRAN. A throat cancer diagnosis led to Mr. Smith’s keen interest in learning more about cancer and biotechnology. He became one of the first board members when HudsonAlpha was formed. The Smith family has supported the Institute since the beginning and continued their generosity over the years to keep HudsonAlpha at the forefront of science and discovery.

“Mark would be thrilled today to see what has happened with HudsonAlpha,” said Smith. “It is one of a kind and the sky’s the limit for HudsonAlpha’s future.”

Barsh studies the genetics of morphological variation – how DNA makes people and animals look different from one another, both within and between species. His research also helps to understand how migration, isolation, and population history affect the ability of wild animals to respond to and cope with changes in climate, habitat and environment.

“It is an honor and privilege to carry the Smith family name, who have been known for their community leadership and philanthropy in Huntsville and beyond,” said Barsh. “Linda was pivotal in bringing me to HudsonAlpha more than a decade ago. We are forever grateful for the family’s investment in HudsonAlpha throughout the years.”

“Mark and Linda really mean a lot to me and the legacy of HudsonAlpha,” said Jim Hudson, HudsonAlpha co-founder. “I am truly thankful for their friendship over the years as well as their support to make the vision for HudsonAlpha a reality.”

The HudsonAlpha Foundation, the philanthropic arm of the Institute, has created the opportunity to name chairs, such as the Smith Family Chair in Genomics, as a way for donors to make an investment in the Institute to ensure its sustainability. In addition, chair positions help increase faculty retention and recruit new talent. For more information, click here.

###

About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha’s vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 40 diverse biotech companies on campus. To learn more about HudsonAlpha, visit hudsonalpha.org.

TUSCALOOSA, Ala. – Three professors specializing in biomedical sciences, biochemistry and bioengineering will join The University of Alabama during the upcoming spring semester, boosting research and innovation in novel design and engineering of advanced drug delivery systems.

Dr. Ravi Kumar will be a professor in the College of Community Health Sciences with an adjunct appointment in the College of Engineering’s Department of Chemical and Biological Engineering. Internationally recognized for his significant contributions to nanomedicine research with applications for the treatment of human health and diseases, Kumar will also lead the convergent bioscience and medicine initiative under the Alabama Life Research Institute.

Along with Kumar, Drs. Meenakshi Arora and Raghu Ganugula will join CCHS as associate professor and assistant professor, respectively. Arora researches the development of biomaterials for therapeutic applications, specifically for autoimmune and inflammatory disease conditions. Ganugula has expertise in biotechnology and pharmacological testing of novel bioactives and drug delivery systems.

The Office for Research and Economic Development, the Office for Academic Affairs and CCHS partnered in support of the research group’s move to UA.

“These three outstanding researchers bring a wealth of experience that will advance the University’s research enterprise through collaboration with our existing faculty while enriching the experience of our students,” said Dr. Russell J. Mumper, UA vice president for research and economic development. “They are among the world leaders working in the critical nexus of bioscience and medicine, and they will continue tackling some of the greatest challenges in improving human health.”

The team will join UA from the Texas A&M University College of Pharmacy, where Kumar leads the premier laboratory in the world in nanotechnology-based oral drug delivery systems. The team currently has about $5.8 million in sponsored research projects, including three Research Project Grants, also known as R01s, from the National Institutes of Health.

“The College of Community Health Sciences is committed to improving care and treatment for those suffering medically, and this team’s ingenuity in targeting drug delivery furthers and expands our mission and opportunity for collaboration that brings benefits to our faculty and clinical professionals,” said Dr. Richard Friend, CCHS dean.

Their lab and convergent bioscience and medicine initiative will be established in the AIME Building as part of ALRI, which brings together researchers from across campus to study problems that directly affect the health and well-being of individuals and communities in Alabama, as well as across the nation and world.

“Advancing solutions in biosciences requires interdisciplinary teams, and the addition of this distinguished group brings another dimension to UA’s ability to better the human condition through new intellectual and technical resources,” said Dr. Sharlene Newman, ALRI executive director.

Kumar works with basic and clinical scientists in establishing novel drug delivery mechanisms and their application to inflammatory, infectious and vascular disease conditions, and his published research is widely followed by other researchers in the field.

He was first to propose and demonstrate a non-competitive active targeting nanosystem and its application to diseases. His lab employed this platform in the treatment of difficult to treat diseases such as lupus, diabetes complications and intraocular inflammation in rodent and canine models respectively. His work has advanced fundamental understanding of blood-intestine and other biological barriers and has led to the development of two patents. These technologies have facilitated industry collaborations, as well as the formation of a spinoff company

In February, Kumar will be inducted into the American Association for the Advancement of Sciences for his contributions to drug delivery. He is also a Foreign Fellow with the European Academy of Sciences, and Fellow with the American Association of Pharmaceutical Sciences, and has received a number of other national and international awards.

His tenure at Texas A&M began in 2013 after about five years as a professor at the University of Strathclyde in the United Kingdom. He was also an assistant professor at the National Institute of Pharmaceutical Education and Research in India, and a research fellow at Saarland University in Germany.

Kumar earned a doctorate in drug delivery from the Indian Institute of Technology Roorkee in 2000, a masters of applied chemistry from Devi Ahilya Vishwavidyalaya and a bachelor’s degree in physical sciences from Nagarjuna University.

Arora is an assistant professor of research at Texas A&M, where she has also been a research scientist. Arora has been an integral member of the research team with Kumar at previous posts, including post-doctoral work in other labs. She earned a doctorate in chemistry in 2001 and a masters of organic chemistry from the Indian Institute of Technology Roorkee as well as a bachelors of chemistry, zoology and botany from Chaudhary Charan Singh University.

At Texas A&M, Ganugula is an assistant professor of research and was previously an assistant research scientist and postdoctoral researcher. He graduated in 2011 with a doctorate in biotechnology from Central Institute of Fisheries Technology in India, a masters in biotechnology from Andhra University and a bachelors of chemistry, botany and zoology from A.M.A.L. College.

https://news.ua.edu/2020/11/biomedical-sciences-team-joins-the-university-of-alabama/

The University of Alabama, the state’s oldest and largest public institution of higher education, is a student-centered research university that draws the best and brightest to an academic community committed to providing a premier undergraduate and graduate education. UA is dedicated to achieving excellence in scholarship, collaboration and intellectual engagement; providing public outreach and service to the state of Alabama and the nation; and nurturing a campus environment that fosters collegiality, respect and inclusivity.

Additional news about The University of Alabama can be found at: https://news.ua.edu/news-media/

A University of Alabama at Birmingham (UAB) faculty member has founded a company to tackle the pervasive problems faced with respiratory diseases.

ResBiotech, a cardio-respiratory health innovation platform company, was recently launched by Dr. Charitharth Vivek Lal to target respiratory diseases like chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma and others. Affecting more than 20 million people in the United States alone, respiratory diseases represent a $50 billion market and show no signs of decreasing.

ResBiotech, which was launched with UAB’s Bill L. Harbert Institute for Innovation and Entrepreneurship and is working with the Birmingham Business Alliance (BBA) and other partners to seek investors, will revolutionize the future of patient care and strengthen Birmingham’s health care and entrepreneurial ecosystems, said Jon Nugent, vice president of innovation and technology for the BBA.

“Birmingham is the right place to launch this type of company because of the continual health care innovation that is one of our region’s trademarks,” said Nugent, who has worked with Dr. Lal for over a year. “There is continued and widespread interest in state-of-the-art health care innovation. Dr. Lal’s vision, coupled with support from UAB and local stakeholders, could prove to be pathbreaking for Birmingham and Alabama as a whole.”

Using medical technologies to solve major health challenges, its first product, ResBiotic – currently in preclinical development – will serve as a wellness supplement for respiratory illnesses in people of all ages.

“The company will be focused on the invention, creation and monetization of proprietary medical technologies that solve major health challenges,” Lal said.

Dr. Sanjay Singh, a local entrepreneur, former UAB faculty and a member of the BBA’s Executive Committee, will serve as the strategic business adviser for ResBiotech. In addition, a Scientific Advisory Board will be created for the company.

“ResBiotech will be an innovation, investment and commercialization vehicle, with access to world-class researchers and facilities locally,” said Singh. “I foresee ResBiotech positioned to become a national leader in the cardio-respiratory innovation industry, one that could revolutionize patient care in the future.”

Dr. Kathy Nugent, executive director of the Bill L. Harbert Institute for Innovation and Entrepreneurship at UAB, emphasized Birmingham’s entrepreneurial ecosystem and Dr. Lal’s board service to Urgent Care for Children, another Birmingham startup that is quickly growing.

“It’s exciting to see research born in the university spin out and grow in Birmingham, as our ecosystem is poised for cultivating innovative concepts,” said Nugent.  

Click here to learn more.

November 18, 2020 (Huntsville, AL) – Three scientists from the HudsonAlpha Institute for Biotechnology were named to the annual Highly Cited Researchers™ 2020 list from Clarivate. The list identifies scientists and social scientists who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade. Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index.

By nature, research builds upon past knowledge. When reporting new research, scientists place their work in the proper context with respect to the past work upon which it builds. This is done by referencing sources of information, also known as citations.

In the research community, citations serve not only as performance indicators for individual scientists or fields of study, but also to create webs of knowledge. Citing other research helps to validate the new work and explain how it fits into, or challenges, the current knowledge in the field.

HudsonAlpha has a strong record of making significant contributions to the research community. This is the seventh year in a row that at least three HudsonAlpha scientists have been named on the Highly Cited Researcher list. This speaks volumes to the expertise and respect that these scientists have in their field of study and beyond.

“HudsonAlpha’s outstanding track record of Highly Cited Researchers is a testament to the impactful foundational research that our Institute prides itself on,” says Rick Myers, PhD, President and Science Director and M. A. Loya Chair in Genomics at the HudsonAlpha Institute for Biotechnology. “Collaborative research is an important pillar on which the spirit of HudsonAlpha was built, and we are proud that our scientists are able to be active contributors to the open flow of research and information in the genomics field.”

Past HudsonAlpha faculty included on the Highly Cited Researcher list include Myers, Devin Absher, PhD, Greg Cooper, PhD, Jane Grimwood, PhD, and Jeremy Schmutz.

The three scientists named to the 2020 list are:

• Faculty Investigator Jane Grimwood, PhD – Cross-field
• Faculty Investigator Jeremy Schmutz – Plant and Animal Science
• Jerry Jenkins, PhD – Cross-field  

Grimwood and Schmutz serve as the co-directors of the HudsonAlpha Genome Sequencing Center. Together with their research teams, they have sequenced well over 150 de novo plant genomes, both for their own research projects and collaborative projects. The de novo plant genomes serve as a foundation for genomic and functional plant research, meaning that hundreds of scientists rely on and utilize the reference genomes created by Grimwood and Schmutz’s group.

Because of their expert status in the plant genomics field, Grimwood and Schmutz are no strangers to the Highly Cited Researcher List, both having been named to the list several times before. In fact, Schmutz has made the list every year since its inception in 2014.

Although Jenkins is a newcomer to the Highly Cited Researcher list this year, he has been a critical part of the Genome Sequencing Center team for nearly a decade. He serves as the Genome Analysis Group Leader and is involved in the generation and improvement of de novo plant genomes.

“Working in the Genome Sequencing Center with Jane and Jeremy over the past decade has given me the opportunity to participate in high-quality research and collaborate with dozens of research groups to help address important questions pertaining to plant science,” says Jenkins. “It is rewarding for me personally to see that our peers recognize the impact the group is having in plant genomics, and we plan to continue to make high quality contributions to address questions in plant science."

Grimwood, Schmutz and Jenkins are three of 6,167 researchers from more than sixty countries and regions recognized this year, 2,650 of which reside in the United States. They are also joined by 26 Nobel Laureates.

“In the race for knowledge, it is human capital that is fundamental and this list identifies and celebrates exceptional individual researchers who are having a great impact on the research community as measured by the rate at which their work is being cited by others,” said David Pendlebury, Senior Citation Analyst at the Institute for Scientific Information at Clarivate.

The full 2020 Highly Cited Researchers list and executive summary can be found online here.

###

About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha’s vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 40 diverse biotech companies on campus. To learn more about HudsonAlpha, visit hudsonalpha.org.

State of Alabama, HudsonAlpha and biotech companies working to track COVID-19 transmission

November 23, 2020 (Huntsville, Ala.) – HudsonAlpha Institute for Biotechnology today announced the ongoing efforts in support of Alabama Governor Kay Ivey’s work to respond to and mitigate COVID-19. Through Alabama’s Coronavirus Relief Fund and the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), $600,000 has been allocated to HudsonAlpha to perform genomic sequencing on positive SARS-CoV-2 samples from people across the state of Alabama.

“All of us at HudsonAlpha are grateful to the state of Alabama for this support to help strengthen our state’s response and planning for this pandemic," said Rick Myers, PhD, President, Science Director and M. A. Loya Chair in Genomics at the HudsonAlpha Institute for Biotechnology. “HudsonAlpha’s genomic research scientists are fully committed to combating this deadly virus.”

There are multiple goals with this COVID-19 initiative including identifying different strains of SARS-CoV-2 virus from all regions of the state, generating longitudinal data to determine changes in the SARS-CoV-2 virus during the pandemic; identifying possible sources of new hotspots of infection in Alabama; surveying for possible emerging strains of virus which could have implications for vaccine development and vaccine efficiency; and adding an Alabama perspective to national and global COVID-19 initiatives through sequencing data generated in the state. The information generated will be provided to the Alabama Department of Public Health and other parties that have critical roles in responding to the pandemic.

Leading this project is co-director of HudsonAlpha’s Genome Sequencing Center, Jane Grimwood, PhD. “Through this initiative with the state, HudsonAlpha aims to provide actionable information to help the collective efforts of policymakers and frontline workers in the fight against the pandemic,” said Grimwood.

HudsonAlpha is currently working with Diatherix-Eurofins Laboratories (HudsonAlpha resident associate company) as provider of the COVID-19 samples. HudsonAlpha is engaging other sources to provide additional samples to extend geographic and demographic coverage throughout the state.

 

###

 

About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to developing and applying scientific advances to health, agriculture, learning, and commercialization. Opened in 2008, HudsonAlpha’s vision is to leverage the synergy between discovery, education, medicine, and economic development in genomic sciences to improve the human condition around the globe. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. The state-of-the-art facilities co-locate nonprofit scientific researchers with entrepreneurs and educators. HudsonAlpha has become a national and international leader in genetics and genomics research and biotech education and fosters more than 40 diverse biotech companies on campus. To learn more about HudsonAlpha, visit hudsonalpha.org.

On the closing day of the first annual Southeast Life Sciences conference, the AdvanSE Life Sciences Conference, we want to congratulation the winners of our awards and PitchRounds.

Southeast Life Sciences awards include awards for best initial funding, best venture funding, best strategic partnership, best M&A, and best IPO. The winners of these are as follows. These awards go back more than a decade from both Southeast BIO and the Southeast Medical Device Association prior to the merger. Some of the biggest success stories from the southeast have been included in these awards and we expect the same big things with our winners this year!

• For best Initial Funding (seed or angel), the winner is Acclinate Genetics, from Huntsville, Alabama.
• For best Venture Funding (>$1mm from institutional investors), the winner is Embody Inc., from Norfolk, VA
• For best Strategic Partnership, the winner is SiO2, of Auburn, Alabama
• For best M&A, the award goes to AskBio, from RTP, NC, which was acquired by Bayer AG.
• For best IPO, the award goes to Shattuck Labs, from Durham, NC and Austin, TX

SE PitchRounds this year took in more than 70 applications from across the region for only 22 slots. These 20 companies represented the most exciting technologies and some of the most experienced entrepreneurs in the region. From the initial 22, we selected four finalists that presented on the closing day of the conference. The finalists were Embody, Inc., Moterum, HeamGen, and Stuart Therapeutics.

The winners from the bipharma/diagnostic group was Stuart Therapeutics.

The winner from  the medtech/digital group was Embody, Inc.

Congratulations to Everyone!

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. The person responsible for making this announcement is David Bishop, Director of Investor Relations.

Croda International Plc (“Croda” or “the Group”), the speciality chemical company that uses smart science to create high performance ingredients and technologies that improve lives, today announces that it has recently entered into an agreement with Pfizer Inc. to supply novel excipients used in the manufacture of a COVID-19 vaccine candidate. The contract with Pfizer runs for five years and awards Croda an initial supply contract for four component excipients used in the production of the vaccine candidate for the first three years of the contract. Demand remains subject to relevant approvals.

Croda’s recently acquired subsidiary, Avanti Polar Lipids, Inc. (“Avanti”), specialises in the development and production of high-purity lipids, to produce research and clinical trial quantities of excipients in order to stabilise formulations and enable delivery into the body by parenteral mechanism (injection) for drug and vaccine applications. Croda’s existing health care business has a 20-year track record in developing IP-rich, innovative technologies for drug delivery systems for the pharmaceutical industry and has been working with Avanti, prior to and since its acquisition by Croda, to refine the complex processes involved in achieving the volumes of high-purity excipients required by its pharmaceutical customers. Croda has reprioritised investment, resources and other projects across the Group over the last few months to focus on the delivery of this project.

Commenting on the new contract, Steve Foots, Chief Executive Officer, said:  

“I’m very proud of Croda’s involvement in the battle to fight the most significant pandemic that we have seen in a generation. The application of our innovative capabilities is testament to the strong progress we have made to create industry-leading drug delivery systems, focused on developing speciality excipients and adjuvants to improve the effectiveness and stability of complex drug actives and vaccines. It is another example of why our Purpose - Smart Science to Improve Lives – sits at the heart of our strategy and will continue to drive our priorities and ambitions in the years ahead.”

Nonprofit Operations & Marketing Internship 

You are intrinsically curious about Alabama’s bioscience industry and are motivated to promote the intellectual and innovative capital that make our state a premier place to invest, start, and grow in bioscience. Under the guidance and supervision of the executive director,  you will support back office operations, marketing, and event planning to further the mission of BIO Alabama, the state affiliate of Biotechnology Innovation Organization (BIO) and the leading advocate for Alabama’s bioeconomy. BIO Alabama is a membership-based professional organization representing the state on a national and international stage. Your role as an intern will be to support the executive director in further connecting our bioscience ecosystem. This internship is for college credit and will follow your instructor’s internship guidelines including minimum hour requirements and deliverables. 

What you will do

• Prepare bi-weekly e-newsletter drafts for executive director’s review and approval.

• Assist with weekly social media posts and engagement.

• Coordinate all details of events (both virtual and in person) including speaker invitations, speaker planning and  preparation, promotion, day of event setup, and event attendee follow-up.

• Conduct market research as needed to better understand the State’s bioscience ecosystem and it’s assets. 

• Update and maintain data in customer management systems (CRM)

• Participate in weekly planning calls with the executive director.

What you already have

• Interest in learning marketing and social media for a state-wide, nonprofit, professional organization. 

• Interest in learning how to plan and implement small/medium scale events.

• Experience conducting research and possess strong written and oral communications skills. 

• Ability to navigate a wide variety of business and social settings and enjoy taking the message of BIO Alabama to individuals and organizations not yet familiar with its mission.

Submit PDF file of Cover Letter & Resume to: Sonia Robinson, Executive Director sonia@bioalabama.com

DEADLINE: January 29, 2021

HUNTSVILLE, Ala. – October 15, 2020 – Kailos Genetics announces the launch of Assure Sentinel, a first-of-its-kind workplace viral suppression program that tests organizations for COVID-19 on a frequent and recurring basis.

The Assure Sentinel program reduces the challenges of COVID-19 testing in the workplace. Samples are acquired using the easy and painless ViraWash™ saliva collection system, eliminating the need for nasopharyngeal swabs. Additionally, testing is performed with ViralPatch™, the company’s proprietary viral capture and sample pooling methodology, and next generation DNA sequencing to decrease costs and increase testing sensitivity.

“Pooling dozens of samples together has been standard in blood banking for decades. The Assure Sentinel program is helping to suppress COVID-19 and returning people to the workplace,” says Brian Pollock, Chief Executive Officer for Kailos Genetics.

Regular COVID-19 testing can mean a reduction in employee anxiety and a rise in confidence and productivity. "Safety is, and has always been, our number one priority during the pandemic, and the Assure Sentinel program is helping us continue to ensure the safety and well-being of our employees," said Julia Michaux-Watkins, Director of Human Resources at HudsonAlpha.

Kailos is offering the workplace testing program to companies, non-profit organizations and schools directly and via partnerships with healthcare organizations. The first partnerships announced include Huntingdon College (Montgomery, AL) and the HudsonAlpha Institute for Biotechnology (Huntsville, AL).

“Since the beginning of the pandemic, Huntingdon College identified access to testing as a key element to our ability to responsibly reopen our campus to our students, faculty and staff for the fall. We have been fortunate to find an Alabama-based partner to provide a reasonably priced, efficient testing option, which has been critical in successfully mitigating the spread of COVID-19 on our campus,” says Jay Dorman, Treasurer and Senior Vice President for Institutional Effectiveness, Planning and Administration at Huntingdon College.

For more information on Kailos Genetics Assure Sentinel program, email media@kailosgenetics.com.

Kailos Genetics is a leader in innovative, cost-effective solutions that make genetic screening accessible to everyone.  Kailos provides genetic and COVID-19 testing through partnerships with physicians, health systems and employers around the world.

###